{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T18:13:48Z","timestamp":1784312028959,"version":"3.55.0"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.humpath.2019.10.007","type":"journal-article","created":{"date-parts":[[2019,10,26]],"date-time":"2019-10-26T17:34:21Z","timestamp":1572111261000},"page":"39-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Something old, something new: liver injury associated with total parenteral nutrition therapy and immune checkpoint inhibitors"],"prefix":"10.1016","volume":"96","author":[{"given":"Cherise","family":"Meyerson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bita V.","family":"Naini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2019.10.007_bb0005","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/hep.28323","article-title":"Categorization of drugs implicated in causing liver injury: critical assessment based on published case reports","volume":"63","author":"Bj\u00f6rnsson","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.humpath.2019.10.007_bb0010","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1001\/archinte.1965.03860140008003","article-title":"Drug-induced liver disease: a penalty for progress","volume":"115","author":"Popper","year":"1965","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.humpath.2019.10.007_bb0015","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.26709","article-title":"Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations","volume":"59","author":"Kleiner","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.humpath.2019.10.007_bb0020","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jhep.2010.11.006","article-title":"Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver","volume":"54","author":"Begriche","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.humpath.2019.10.007_bb0025","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1097\/01.pas.0000208896.92988.fc","article-title":"Glycogen pseudoground glass change in hepatocytes","volume":"30","author":"Wisell","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2019.10.007_bb0030","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1053\/j.gastro.2006.07.006","article-title":"Ground-glass, polyglucosan-like hepatocellular inclusions: a \u201cnew\u201d diagnostic entity","volume":"131","author":"Lefkowitch","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.humpath.2019.10.007_bb0035","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-3476(71)80289-5","article-title":"Total parenteral nutrition","volume":"78","author":"Peden","year":"1971","journal-title":"J Pediatr"},{"key":"10.1016\/j.humpath.2019.10.007_bb0040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/hep.20997","article-title":"Parenteral nutrition-associated liver disease and the role for isolated intestine and intestine\/liver transplantation","volume":"43","author":"Buchman","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.humpath.2019.10.007_bb0045","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.cld.2018.12.009","article-title":"Intestinal failure-associated liver disease","volume":"23","author":"Pironi","year":"2019","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.humpath.2019.10.007_bb0050","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.clnu.2018.07.006","article-title":"Clinical approach to the management of intestinal failure associated liver disease (IFALD) in adults: a position paper from the home artificial nutrition and chronic intestinal failure special interest group of ESPEN","volume":"37","author":"Lal","year":"2018","journal-title":"Clin Nutr"},{"key":"10.1016\/j.humpath.2019.10.007_bb0055","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cld.2015.08.009","article-title":"Total parenteral nutrition-induced cholestasis: prevention and management","volume":"20","author":"Beath","year":"2016","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.humpath.2019.10.007_bb0060","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/MPG.0000000000000586","article-title":"Intestinal failure-associated liver disease: a position paper of the ESPGHAN Working Group of Intestinal Failure and Intestinal Transplantation","volume":"60","author":"Lacaille","year":"2015","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.humpath.2019.10.007_bb0065","doi-asserted-by":"crossref","first-page":"525","DOI":"10.7326\/0003-4819-132-7-200004040-00003","article-title":"Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure","volume":"132","author":"Cavicchi","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.humpath.2019.10.007_bb0070","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1055\/s-0036-1597771","article-title":"The differentiation of intestinal-failure-associated liver disease from nonalcoholic fatty liver and nonalcoholic steatohepatitis","volume":"37","author":"Buchman","year":"2017","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.humpath.2019.10.007_bb0075","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.clnu.2017.04.013","article-title":"Clinical classification of adult patients with chronic intestinal failure due to benign disease: an international multicenter cross-sectional survey","volume":"37","author":"Pironi","year":"2018","journal-title":"Clin Nutr"},{"key":"10.1016\/j.humpath.2019.10.007_bb0080","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.clnu.2018.04.019","article-title":"Assessment of intestinal failure associated liver disease according to different diagnostic criteria","volume":"38","author":"Sasdelli","year":"2019","journal-title":"Clin Nutr"},{"key":"10.1016\/j.humpath.2019.10.007_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nu9090987","article-title":"Parenteral nutrition-associated liver disease: the role of the gut microbiota","volume":"9","author":"Cahova","year":"2017","journal-title":"Nutrients"},{"key":"10.1016\/j.humpath.2019.10.007_bb0090","doi-asserted-by":"crossref","unstructured":"Denton C, Price A, Friend J, Manithody C, Blomenkamp K, Westrich M, et al. Role of the gut\u2212liver axis in driving parenteral nutrition-associated injury. Child (Basel, Switzerland) 2018;5:136. https:\/\/doi.org\/10.3390\/children5100136.","DOI":"10.3390\/children5100136"},{"key":"10.1016\/j.humpath.2019.10.007_bb0095","doi-asserted-by":"crossref","unstructured":"Neelis E, de Koning B, Rings E, Wijnen R, Nichols B, Hulst J, et al. The gut microbiome in patients with intestinal failure: current evidence and implications for clinical practice. JPEN J Parenter Enteral Nutr 2019;43:194\u2013205. https:\/\/doi.org\/10.1002\/jpen.1423.","DOI":"10.1002\/jpen.1423"},{"key":"10.1016\/j.humpath.2019.10.007_bb0100","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2005.10.066","article-title":"Intestinal failure-associated liver disease: what do we know today?","volume":"130","author":"Kelly","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.humpath.2019.10.007_bb0105","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1177\/0148607117709196","article-title":"Intravenous fish oil and pediatric intestinal failure-associated liver disease: changes in plasma phytosterols, cytokines, and bile acids and erythrocyte fatty acids","volume":"42","author":"Calkins","year":"2018","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"10.1016\/j.humpath.2019.10.007_bb0110","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1177\/0148607116637855","article-title":"Parenteral plant sterols accumulate in the liver reflecting their increased serum levels and portal inflammation in children with intestinal failure","volume":"41","author":"Hukkinen","year":"2017","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"10.1016\/j.humpath.2019.10.007_bb0115","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/S0022-3468(96)90507-2","article-title":"Parenteral nutrition-related cholestasis in postsurgical neonates: multivariate analysis of risk factors","volume":"31","author":"Beath","year":"1996","journal-title":"J Pediatr Surg"},{"key":"10.1016\/j.humpath.2019.10.007_bb0120","first-page":"567","article-title":"Hepatobiliary consequences of parenteral alimentation","volume":"9","author":"Balistreri","year":"1990","journal-title":"Prog Liver Dis"},{"key":"10.1016\/j.humpath.2019.10.007_bb0125","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1365-2559.1982.tb02774.x","article-title":"Total parenteral nutrition-induced cholestasis mimicking large bile duct obstruction","volume":"6","author":"Body","year":"1982","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2019.10.007_bb0130","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1055\/s-2008-1040545","article-title":"Hepatobiliary abnormalities associated with total parenteral nutrition","volume":"8","author":"Klein","year":"1988","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.humpath.2019.10.007_bb0135","first-page":"190","article-title":"Total parenteral nutrition: a histopathologic analysis of the liver changes in 20 children","volume":"7","author":"Mullick","year":"1994","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2019.10.007_bb0140","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10024-001-0154-7","article-title":"Total parenteral nutrition induced liver pathology: an autopsy series of 24 newborn cases","volume":"7","author":"Zambrano","year":"2004","journal-title":"Pediatr Dev Pathol"},{"key":"10.1016\/j.humpath.2019.10.007_bb0145","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1542\/peds.64.3.342","article-title":"Intrahepatic cholestasis associated with parenteral nutrition in premature infants","volume":"64","author":"Beale","year":"1979","journal-title":"Pediatrics"},{"key":"10.1016\/j.humpath.2019.10.007_bb0150","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/ajcp\/76.3.276","article-title":"Hepatobiliary dysfunction in infants and children associated with long-term total parenteral nutrition. A clinico-pathologic study","volume":"76","author":"Benjamin","year":"1981","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2019.10.007_bb0155","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0016-5085(87)90859-6","article-title":"Development of hepatic cholestasis and fibrosis in patients with massive loss of intestine supported by prolonged parenteral nutrition","volume":"92","author":"Stanko","year":"1987","journal-title":"Gastroenterology"},{"key":"10.1016\/j.humpath.2019.10.007_bb0160","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0022-3476(85)80360-7","article-title":"Hepatocellular carcinoma in a noncirrhotic infant after prolonged parenteral nutrition","volume":"106","author":"Patterson","year":"1985","journal-title":"J Pediatr"},{"key":"10.1016\/j.humpath.2019.10.007_bb0165","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0022-3476(82)80242-4","article-title":"Liver malignancy after parenteral nutrition","volume":"100","author":"Vileisis","year":"1982","journal-title":"J Pediatr"},{"key":"10.1016\/j.humpath.2019.10.007_bb0170","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/MPG.0b013e31822cde6a","article-title":"Hepatocellular carcinoma in a child with intestinal failure-associated liver disease","volume":"54","author":"Yeop","year":"2012","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.humpath.2019.10.007_bb0175","first-page":"152","article-title":"Pediatric total parenteral nutrition","volume":"105","author":"Cohen","year":"1981","journal-title":"Liver histopathology Arch Pathol Lab Med"},{"key":"10.1016\/j.humpath.2019.10.007_bb0180","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/0016-5085(81)90663-6","article-title":"Serial liver biopsies in parenteral nutrition-associated cholestasis of early infancy","volume":"81","author":"Dahms","year":"1981","journal-title":"Gastroenterology"},{"key":"10.1016\/j.humpath.2019.10.007_bb0185","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/0002-9343(87)90449-9","article-title":"Hepatic complications of total parenteral nutrition","volume":"82","author":"Baker","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.humpath.2019.10.007_bb0190","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1001\/jama.1979.03290480032019","article-title":"Liver function values in adults receiving total parenteral nutrition","volume":"241","author":"Lindor","year":"1979","journal-title":"JAMA"},{"key":"10.1016\/j.humpath.2019.10.007_bb0195","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/0016-5085(93)90864-9","article-title":"Hepatobiliary complications of total parenteral nutrition","volume":"104","author":"Quigley","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1016\/j.humpath.2019.10.007_bb0200","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000171453","article-title":"Hepatobiliary complications in adults receiving nutrition support","volume":"12","author":"Fleming","year":"1994","journal-title":"Dig Dis"},{"key":"10.1016\/j.humpath.2019.10.007_bb0205","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/014860718500900111","article-title":"Does long-term home parenteral nutrition in adult patients cause chronic liver disease?","volume":"9","author":"Bowyer","year":"2000","journal-title":"J Parenter Enteral Nutr"},{"key":"10.1016\/j.humpath.2019.10.007_bb0210","first-page":"573","article-title":"Serum hepatic enzyme and bilirubin elevations during parenteral nutrition","volume":"145","author":"Grant","year":"1977","journal-title":"Surg Gynecol Obstet"},{"key":"10.1016\/j.humpath.2019.10.007_bb0215","doi-asserted-by":"crossref","unstructured":"Abstracts from USCAP 2019: liver pathology (1509-1580). Mod Pathol 2019;32:1\u201364. https:\/\/doi.org\/10.1038\/s41379-019-0230-z.","DOI":"10.1038\/s41379-019-0230-z"},{"key":"10.1016\/j.humpath.2019.10.007_bb0220","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.humpath.2011.07.008","article-title":"Total parenteral nutrition therapy and liver injury: a histopathologic study with clinical correlation","volume":"43","author":"Naini","year":"2012","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2019.10.007_bb0225","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/MOT.0b013e32834670eb","article-title":"The impact of intravenous fish oil emulsions on pediatric intestinal failure-associated liver disease","volume":"16","author":"Venick","year":"2011","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.humpath.2019.10.007_bb0230","doi-asserted-by":"crossref","first-page":"e678","DOI":"10.1542\/peds.2007-2248","article-title":"Safety and efficacy of a fish-oil\u2013based fat emulsion in the treatment of parenteral nutrition-associated liver disease","volume":"121","author":"Gura","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.humpath.2019.10.007_bb0235","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/SLA.0b013e3181b36657","article-title":"Parenteral fish oil improves outcomes in patients with parenteral nutrition\u2013associated liver injury","volume":"250","author":"Puder","year":"2009","journal-title":"Ann Surg"},{"key":"10.1016\/j.humpath.2019.10.007_bb0240","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/MPG.0b013e318182c8f6","article-title":"Changing the paradigm: omegaven for the treatment of liver failure in pediatric short bowel syndrome","volume":"48","author":"Diamond","year":"2009","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.humpath.2019.10.007_bb0245","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1203\/PDR.0b013e3181bbdf2b","article-title":"Impact of fish oil\u2013based lipid emulsion on serum triglyceride, bilirubin, and albumin levels in children with parenteral nutrition\u2013associated liver disease","volume":"66","author":"Lee","year":"2009","journal-title":"Pediatr Res"},{"key":"10.1016\/j.humpath.2019.10.007_bb0250","doi-asserted-by":"crossref","unstructured":"Ekema G, Falchetti D, Boroni G, Tanca AR, Altana C, Righetti L, et al. Reversal of severe parenteral nutrition\u2013associated liver disease in an infant with short bowel syndrome using parenteral fish oil (omega-3 fatty acids). J Pediatr Surg 2008;43:1191\u20135. https:\/\/doi.org\/10.1016\/j.jpedsurg.2008.01.005.","DOI":"10.1016\/j.jpedsurg.2008.01.005"},{"key":"10.1016\/j.humpath.2019.10.007_bb0255","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.clnu.2011.10.001","article-title":"Effect of omega-3 polyunsaturated fatty acids to reverse biopsy-proven parenteral nutrition\u2013associated liver disease in adults","volume":"31","author":"Xu","year":"2012","journal-title":"Clin Nutr"},{"key":"10.1016\/j.humpath.2019.10.007_bb0260","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1177\/0148607110382023","article-title":"Omega-3\u2013enriched lipid emulsion for liver salvage in parenteral nutrition\u2013induced cholestasis in the adult patient","volume":"35","author":"Jurewitsch","year":"2011","journal-title":"J Parenter Enteral Nutr"},{"key":"10.1016\/j.humpath.2019.10.007_bb0265","doi-asserted-by":"crossref","unstructured":"Matsumoto CS, Kaufman SS, Island ER, Kallakury B, Yazigi NA, Khan KM, et al. Hepatic explant pathology of pediatric intestinal transplant recipients previously treated with omega-3 fatty acid lipid emulsion. J Pediatr 2014;165:59\u201364. https:\/\/doi.org\/10.1016\/j.jpeds.2014.03.034.","DOI":"10.1016\/j.jpeds.2014.03.034"},{"key":"10.1016\/j.humpath.2019.10.007_bb0270","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jpeds.2009.08.033","article-title":"Failure of resolution of portal fibrosis during omega-3 fatty acid lipid emulsion therapy in two patients with irreversible intestinal failure","volume":"156","author":"Soden","year":"2010","journal-title":"J Pediatr"},{"key":"10.1016\/j.humpath.2019.10.007_bb0275","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/MPG.0b013e31827e208c","article-title":"Hepatic fibrosis persists and progresses despite biochemical improvement in children treated with intravenous fish oil emulsion","volume":"56","author":"Mercer","year":"2013","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.humpath.2019.10.007_bb0280","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jpedsurg.2017.01.048","article-title":"Persistence of hepatic fibrosis in pediatric intestinal failure patients treated with intravenous fish oil lipid emulsion","volume":"52","author":"Belza","year":"2017","journal-title":"J Pediatr Surg"},{"key":"10.1016\/j.humpath.2019.10.007_bb0285","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.humpath.2019.10.007_bb0290","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.humpath.2019.10.007_bb0295","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1634\/theoncologist.2015-0509","article-title":"Immune checkpoint inhibitors: review and management of endocrine adverse events","volume":"21","author":"Gonz\u00e1lez-Rodr\u00edguez","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.humpath.2019.10.007_bb0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0346-6","article-title":"Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson","volume":"6","author":"Wang","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.humpath.2019.10.007_bb0305","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/PAS.0b013e31817150e3","article-title":"\u03b1-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis","volume":"32","author":"Oble","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2019.10.007_bb0310","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/imr.12531","article-title":"Introduction to checkpoint inhibitors and cancer immunotherapy","volume":"276","author":"Sharpe","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.humpath.2019.10.007_bb0315","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11901-018-0408-8","article-title":"Knowns and unknowns: the safety and efficacy of cancer immunotherapy in chronic liver disease","volume":"17","author":"Chascsa","year":"2018","journal-title":"Curr Hepatol Reports"},{"key":"10.1016\/j.humpath.2019.10.007_bb0320","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/ijc.30678","article-title":"Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis of published data","volume":"141","author":"Wang","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.humpath.2019.10.007_bb0325","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/COC.0000000000000374","article-title":"Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma","volume":"41","author":"Huffman","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.humpath.2019.10.007_bb0330","doi-asserted-by":"crossref","unstructured":"Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015;372:2006\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1414428.","DOI":"10.1056\/NEJMoa1414428"},{"key":"10.1016\/j.humpath.2019.10.007_bb0335","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2019.10.007_bb0340","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2019.10.007_bb0345","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2016.72.1167","article-title":"Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma","volume":"35","author":"Sznol","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2019.10.007_bb0350","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4103\/JIPO.JIPO_12_18","article-title":"The impact of immune checkpoint inhibitor-related adverse events and their immunosuppressive treatment on patients' outcomes","volume":"1","author":"Abu-Sbeih","year":"2018","journal-title":"J Immunother Precis Oncol"},{"key":"10.1016\/j.humpath.2019.10.007_bb0355","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/liv.13746","article-title":"Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents","volume":"38","author":"Suzman","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.humpath.2019.10.007_bb0360","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.humpath.2019.10.007_bb0365","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/17425255.2019.1574744","article-title":"Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies","volume":"15","author":"Jennings","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.humpath.2019.10.007_bb0370","article-title":"Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory","volume":"64","author":"Friend","year":"2017","journal-title":"metastatic hepatocellular carcinoma Pediatr Blood Cancer"},{"key":"10.1016\/j.humpath.2019.10.007_bb0375","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1177\/2050640618774631","article-title":"Use of checkpoint inhibitors in liver transplant recipients","volume":"6","author":"Munker","year":"2018","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.humpath.2019.10.007_bb0380","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1055\/s-0038-1667358","article-title":"Liver toxicity with cancer checkpoint inhibitor therapy","volume":"38","author":"Nadeau","year":"2018","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.humpath.2019.10.007_bb0385","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s41379-018-0013-y","article-title":"Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury","volume":"31","author":"Zen","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2019.10.007_bb0390","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1007\/s10620-012-2140-5","article-title":"Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma","volume":"57","author":"Kleiner","year":"2012","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.humpath.2019.10.007_bb0395","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/PAS.0000000000000453","article-title":"Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases","volume":"39","author":"Johncilla","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2019.10.007_bb0400","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"De Martin","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.humpath.2019.10.007_bb0405","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/PAS.0000000000000759","article-title":"Fibrin ring granulomas in checkpoint inhibitor-induced hepatitis","volume":"41","author":"Everett","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2019.10.007_bb0410","first-page":"491","article-title":"The liver lesion in Q fever","volume":"116","author":"Bernstein","year":"1965","journal-title":"Clinical and pathologic features. Arch Intern Med"},{"key":"10.1016\/j.humpath.2019.10.007_bb0415","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0046-8177(80)80105-5","article-title":"Granulomatous hepatitis in Q fever","volume":"11","author":"Pellegrin","year":"1980","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2019.10.007_bb0420","doi-asserted-by":"crossref","unstructured":"Aguilar-Olivos N, del Carmen Manzano-Robleda M, Guti\u00e9rrez-Grobe Y, Chabl\u00e9-Montero F, Albores-Saavedra J, L\u00f3pez-M\u00e9ndez E. Granulomatous hepatitis caused by Q fever: a differential diagnosis of fever of unknown origin. Ann Hepatol 2019;12:138\u201341. https:\/\/doi.org\/10.1016\/S1665-2681(19)31396-1.","DOI":"10.1016\/S1665-2681(19)31396-1"},{"key":"10.1016\/j.humpath.2019.10.007_bb0425","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.jhep.2018.08.014","article-title":"Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: a retrospective study","volume":"69","author":"Parlati","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.humpath.2019.10.007_bb0430","doi-asserted-by":"crossref","unstructured":"Doherty GJ, Duckworth AM, Davies SE, Mells GF, Brais R, Harden S V, et al. Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor\u2013induced hepatotoxicity driven by biliary injury. ESMO Open 2017;2:e000268. https:\/\/doi.org\/10.1136\/esmoopen-2017\u2013000268.","DOI":"10.1136\/esmoopen-2017-000268"},{"key":"10.1016\/j.humpath.2019.10.007_bb0435","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10637-017-0453-0","article-title":"Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non\u2013small cell lung cancer","volume":"35","author":"Kawakami","year":"2017","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.humpath.2019.10.007_bb0440","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/hep.30189","article-title":"Antiprogrammed cell death-1 immunotherapy-related secondary sclerosing cholangitis","volume":"69","author":"Ogawa","year":"2019","journal-title":"Hepatology"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817719301832?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817719301832?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T16:36:52Z","timestamp":1758645412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817719301832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":88,"alternative-id":["S0046817719301832"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2019.10.007","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Something old, something new: liver injury associated with total parenteral nutrition therapy and immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2019.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}